FDA One Step Closer To Makena Withdrawal After Hearing Officer Echoes Advisory Panel’s Advice
Executive Summary
In a memo to Commissioner Califf and Chief Scientist Bumpus, Celia Witten focuses the final Makena decisionmakers on the key factors she believes should be used to determine the drug’s market status.
You may also be interested in...
FDA’s Pepaxto Decider: Peter Marks To Handle Oncopeptides’ Appeal Of Accelerated Approval Withdrawal
CBER director will decide whether the multiple myeloma drug should be withdrawn under new expedited withdrawal procedures; it's the third time FDA leaders have asked senior officials in the biologics center to help decide the fate of a CDER-regulated accelerated approval drug.
Makena Enforcement Discretion, Compounding Still In Limbo Post Long-Awaited Withdrawal
US FDA Commissioner and Chief Scientist call for immediate withdrawal of the preterm birth prevention drug and generic versions but defer to the Center for Drug Evaluation and Research on how to implement key lingering details.
Makena: Formal Withdrawal Order Would Provide ‘Greater Certainty,’ Transparency – CDER
Final decision by the Office of Commissioner would provide more certainty than Covis’ proposal to voluntarily withdraw Makena ‘at some point in the future’ and assure that generic versions of the preterm birth prevention drug come off the market at the same time, the US FDA’s drugs center tells the Pink Sheet.